SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier
Trade name BETANAL QUATTRO
Product code (UVP) 06367933

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use Herbicide
EPA-Nr. HSR100882

1.3 Details of the supplier of the safety data sheet
Supplier Bayer New Zealand Limited
3 Argus Place, Hillcrest
Auckland 0627
New Zealand
Telephone 0800 428 246
Telefax (09) 441 8645

1.4 Emergency telephone no.
Emergency Number 0800 734 607 (24hr)
Global Incident Response Hotline (24h) +1 (760) 476-3964 (Company 3E for Bayer AG, Crop Science Division)

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture
Classified as hazardous according to the criteria in the Hazardous Substances (Minimum Degrees of Hazard) Regulations 2001

6.1D H332 Harmful if inhaled.
6.9B H373 May cause damage to organs through prolonged or repeated exposure.
9.1B H411 Toxic to aquatic life with long lasting effects.
9.2A H421 Very toxic to the soil environment.
9.3C H433 Harmful to terrestrial vertebrates.

2.2 Label elements
Labelling in accordance with Hazardous Substances Identification Regulations 2001
Hazard label for supply/use required.

Signal word: Warning

Hazard statements

H332 Harmful if inhaled.
H373 May cause damage to organs through prolonged or repeated exposure.
H411 Toxic to aquatic life with long lasting effects.
H421 Very toxic to the soil environment.
H433 Harmful to terrestrial vertebrates.

Precautionary statements

P102 Keep out of reach of children.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P391 Collect spillage.
P314 Get medical advice/ attention if you feel unwell.
P501 Dispose of contents/container in accordance with local regulation.

2.3 Other hazards

No other hazards known.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures

Chemical nature

Suspo-emulsion (SE)
5.5% Phenmedipham (60 g/l), 5.5% Desmedipham (60 g/l), 5.5% Ethofumesate (60 g/l), 18.3% Metamitron (200 g/l)

Hazardous components

<table>
<thead>
<tr>
<th>Name</th>
<th>CAS-No.</th>
<th>Conc. [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenmedipham</td>
<td>13684-63-4</td>
<td>5.50</td>
</tr>
<tr>
<td>Desmedipham</td>
<td>13684-56-5</td>
<td>5.50</td>
</tr>
<tr>
<td>Ethofumesate</td>
<td>26225-79-6</td>
<td>5.50</td>
</tr>
<tr>
<td>Metamitron</td>
<td>41394-05-2</td>
<td>18,30</td>
</tr>
<tr>
<td>Ammonium distyrylphenyl ether sulphate</td>
<td>59891-11-1</td>
<td>&gt;= 1,0 – &lt; 3.0</td>
</tr>
<tr>
<td>Fatty alcohol ethoxylate</td>
<td>68131-39-5</td>
<td>&gt;= 0,1 – &lt; 1</td>
</tr>
<tr>
<td>1,2-Benzisothiazol-3(2H)-one</td>
<td>2634-33-5</td>
<td>&gt;= 0,005 – &lt; 0,05</td>
</tr>
</tbody>
</table>

Further information

<table>
<thead>
<tr>
<th>Phenmedipham</th>
<th>13684-63-4</th>
<th>M-Factor: 1 (acute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desmedipham</td>
<td>13684-56-5</td>
<td>M-Factor: 10 (acute), 10 (chronic)</td>
</tr>
</tbody>
</table>
SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

General advice
Move out of dangerous area. Place and transport victim in stable position (lying sideways). Remove contaminated clothing immediately and dispose of safely.

Inhalation
Move to fresh air. Keep patient warm and at rest. Call a physician or poison control center immediately.

Skin contact
Wash off thoroughly with plenty of soap and water, if available with polyethyleneglycol 400, subsequently rinse with water. If symptoms persist, call a physician.

Eye contact
Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation develops and persists.

Ingestion
Rinse mouth. Do NOT induce vomiting. Call a physician or poison control center immediately.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms
Tiredness, Headache, Trembling, Lethargy, Dyspnoea, Ataxia

4.3 Indication of any immediate medical attention and special treatment needed

Risks
This product, although being a carbamate, is NOT a cholinesterase inhibitor.

Treatment
Treat symptomatically. In case of ingestion gastric lavage should be considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium sulphate is always advisable. There is no specific antidote. Forced alkaline diuresis and hemodialysis may be considered.

Contact the National Poisons and Hazardous Chemicals Information center in Dunedin, PO Box 913, Dunedin. Phone 0800 POISON (0800 764 766).

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable
Water spray, Carbon dioxide (CO2), Foam, Sand

Unsuitable
High volume water jet

5.2 Special hazards arising from the substance or mixture

In the event of fire the following may be released: Hydrogen cyanide (hydrocyanic acid), Carbon monoxide (CO), Sulphur oxides, Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for firefighters
In the event of fire and/or explosion do not breathe fumes. In the event of fire, wear self-contained breathing apparatus.
Further information
Contain the spread of the fire-fighting media. Do not allow run-off from fire fighting to enter drains or water courses.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures
Precautions
Avoid contact with spilled product or contaminated surfaces. Use personal protective equipment.

6.2 Environmental precautions
Do not allow to get into surface water, drains and ground water.

6.3 Methods and materials for containment and cleaning up
Methods for cleaning up
Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Collect and transfer the product into a properly labelled and tightly closed container.

Additional advice
Check also for any local site procedures.

6.4 Reference to other sections
Information regarding safe handling, see section 7.
Information regarding personal protective equipment, see section 8.
Information regarding waste disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling
Advice on safe handling
Use only in area provided with appropriate exhaust ventilation.

Advice on protection against fire and explosion
No special precautions required.

Hygiene measures
Avoid contact with skin, eyes and clothing. Keep working clothes separately. Wash hands immediately after work, if necessary take a shower. Remove soiled clothing immediately and clean thoroughly before using again.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers
Store in original container. Store in a place accessible by authorized persons only. Keep containers tightly closed in a dry, cool and well-ventilated place. Protect from frost. Keep away from direct sunlight.

Advice on common storage
Keep away from food, drink and animal feedingstuffs.

Suitable materials
HDPE (high density polyethylene)

7.3 Specific end use(s)
Refer to the label and/or leaflet.
SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters</th>
<th>Update</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenmedipham</td>
<td>13684-63-4</td>
<td>1,5 mg/m³ (TWA)</td>
<td></td>
<td>OES BCS*</td>
</tr>
<tr>
<td>Desmedipham</td>
<td>13684-56-5</td>
<td>1,2 mg/m³ (TWA)</td>
<td></td>
<td>OES BCS*</td>
</tr>
<tr>
<td>Ethofumesate</td>
<td>26225-79-6</td>
<td>10 mg/m³ (TWA)</td>
<td></td>
<td>OES BCS*</td>
</tr>
</tbody>
</table>

*OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

8.2 Exposure controls

Personal protective equipment

In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the following recommendations would apply.

Respiratory protection

Respiratory protection is not required under anticipated circumstances of exposure.

Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer’s instructions regarding wearing and maintenance.

Hand protection

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the contact time.

Wash gloves when contaminated. Dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating, drinking, smoking or using the toilet.

Material: Nitrile rubber
Rate of permeability: > 480 min
Glove thickness: > 0,4 mm
Protective index: Class 6

Eye protection

Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

Skin and body protection

Wear standard coveralls and Category 3 Type 4 suit.

If there is a risk of significant exposure, consider a higher protective type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and should be professionally laundered frequently.

If chemical protection suit is splashed, sprayed or significantly contaminated, decontaminate as far as possible, then carefully remove and dispose of as advised by manufacturer.

General protective measures

If product is handled while not enclosed, and if contact may occur:

Complete suit protecting against chemicals
SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Form: suspension
Colour: white to light beige
Odour: aromatic
pH: 4.0 - 7.0 at 10% (23 °C) (deionized water)
Flash point: > 100 °C
No flash point - Determination conducted up to the boiling point.
Density: ca. 1.09 g/cm³ at 20 °C
Water solubility: dispersible
Partition coefficient: n-octanol/water
Phenmedipham: log Pow: 3.59
Desmedipham: log Pow: 3.39
Ethofumesate: log Pow: 2.7 at 25 °C
Metamitron: log Pow: 0.86
Viscosity, dynamic:
150 - 350 mPa.s at 20 °C Velocity gradient 20 /s
50 - 160 mPa.s at 20 °C Velocity gradient 100 /s
Surface tension: ca. 39 mN/m
Determined as a 0.1% solution in distilled water (1 g/l).

9.2 Other information
Further safety related physical-chemical data are not known.

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity
Thermal decomposition: Stable under normal conditions.
10.2 Chemical stability
Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions
No hazardous reactions when stored and handled according to prescribed instructions.
10.4 Conditions to avoid
Extremes of temperature and direct sunlight.
10.5 Incompatible materials
Store only in the original container.
10.6 Hazardous decomposition products
No decomposition products expected under normal conditions of use.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects
Acute oral toxicity  LD50 (Rat) > 2.000 mg/kg
Acute inhalation toxicity  During intended and foreseen applications, no respirable aerosol is formed.
Acute dermal toxicity  LD50 (Rat) > 4.000 mg/kg
Skin irritation  No skin irritation (Rabbit)
Eye irritation  Slight irritant effect - does not require labelling. (Rabbit)
Sensitisation  Non-sensitizing. (Guinea pig)
OECD Test Guideline 406, Buehler test
OECD Test Guideline 429, local lymph node assay (LLNA)

Assessment STOT Specific target organ toxicity – single exposure
Phenmedipham: Based on available data, the classification criteria are not met.
Desmedipham: Based on available data, the classification criteria are not met.
Ethofumesate: Based on available data, the classification criteria are not met.
Metamitron: Based on available data, the classification criteria are not met.

Assessment STOT Specific target organ toxicity – repeated exposure
Phenmedipham caused haemolytic anaemia, methaemoglobinaemia in animal studies. The observed effects do not appear to be relevant for humans.
Desmedipham caused methaemoglobinaemia, haemolytic anaemia in animal studies. The observed effects do not appear to be relevant for humans.
Ethofumesate did not cause specific target organ toxicity in experimental animal studies.
Metamitron did not cause specific target organ toxicity in experimental animal studies.

Assessment mutagenicity
Phenmedipham was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.
Desmedipham was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.
Ethofumesate was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.
Metamitron was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Assessment carcinogenicity
Phenmedipham was not carcinogenic in lifetime feeding studies in rats and mice.
Desmedipham was not carcinogenic in lifetime feeding studies in rats and mice.
Ethofumesate was not carcinogenic in lifetime feeding studies in rats and mice.
Metamitron was not carcinogenic in lifetime feeding studies in rats and mice.

Assessment toxicity to reproduction
Phenmedipham caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Phenmedipham is related to parental toxicity.
Desmedipham caused a reduced litter size and a reduced pup weight. The reproduction toxicity seen with Desmedipham is related to parental toxicity.
Ethofumesate did not cause reproductive toxicity in a two-generation study in rats.
Metamitron did not cause reproductive toxicity in a two-generation study in rats.

Assessment developmental toxicity
Phenmedipham caused developmental toxicity only at dose levels toxic to the dams. Phenmedipham caused a delayed ossification of foetuses. The developmental effects seen with Phenmedipham are related to maternal toxicity.
Desmedipham caused developmental toxicity only at dose levels toxic to the dams. Desmedipham caused a delayed ossification of foetuses, an increased incidence of variations. The developmental effects seen with Desmedipham are related to maternal toxicity.
Ethofumesate did not cause developmental toxicity in rats and rabbits.
Metamitron did not cause developmental toxicity in rats and rabbits.

**Aspiration hazard**
Based on available data, the classification criteria are not met.

### SECTION 12: ECOLOGICAL INFORMATION

#### 12.1 Toxicity

<table>
<thead>
<tr>
<th>Class</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Toxicity to fish</strong></td>
<td></td>
</tr>
<tr>
<td>LC50 (Oncorhynchus mykiss (rainbow trout))</td>
<td>35 mg/l static test; Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>Toxicity to aquatic invertebrates</strong></td>
<td></td>
</tr>
<tr>
<td>EC50 (Daphnia magna (Water flea))</td>
<td>8,2 mg/l static test; Exposure time: 48 h</td>
</tr>
<tr>
<td><strong>Chronic toxicity to aquatic invertebrates</strong></td>
<td></td>
</tr>
<tr>
<td>NOEC (Daphnia (water flea)):</td>
<td>0,01 mg/l Exposure time: 21 d</td>
</tr>
<tr>
<td>The value mentioned relates to the active ingredient desmedipham.</td>
<td></td>
</tr>
<tr>
<td><strong>Toxicity to aquatic plants</strong></td>
<td></td>
</tr>
<tr>
<td>IC50 (Desmodesmus subspicatus (green algae))</td>
<td>8,6 mg/l static test; Exposure time: 72 h</td>
</tr>
</tbody>
</table>

#### 12.2 Persistence and degradability

<table>
<thead>
<tr>
<th>Class</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biodegradability</strong></td>
<td></td>
</tr>
<tr>
<td>Phenmedipham:</td>
<td>Not rapidly biodegradable</td>
</tr>
<tr>
<td>Desmedipham:</td>
<td>Not rapidly biodegradable</td>
</tr>
<tr>
<td>Ethofumesate:</td>
<td>Not rapidly biodegradable</td>
</tr>
<tr>
<td>Metamitron:</td>
<td>Not rapidly biodegradable</td>
</tr>
<tr>
<td><strong>Koc</strong></td>
<td></td>
</tr>
<tr>
<td>Phenmedipham:</td>
<td>Koc: 888</td>
</tr>
<tr>
<td>Desmedipham:</td>
<td>Koc: &gt; 5000</td>
</tr>
<tr>
<td>Ethofumesate:</td>
<td>Koc: 147</td>
</tr>
<tr>
<td>Metamitron:</td>
<td>Koc: 86,4</td>
</tr>
</tbody>
</table>

#### 12.3 Bioaccumulative potential

<table>
<thead>
<tr>
<th>Class</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioaccumulation</strong></td>
<td></td>
</tr>
<tr>
<td>Phenmedipham:</td>
<td>Bioconcentration factor (BCF) 165 Does not bioaccumulate.</td>
</tr>
<tr>
<td>Desmedipham:</td>
<td>Bioconcentration factor (BCF) 157 Does not bioaccumulate.</td>
</tr>
<tr>
<td>Ethofumesate:</td>
<td>Bioconcentration factor (BCF) 144 Does not bioaccumulate.</td>
</tr>
<tr>
<td>Metamitron:</td>
<td></td>
</tr>
</tbody>
</table>
Does not bioaccumulate.

12.4 Mobility in soil

Mobility in soil
- Phenmedipham: Slightly mobile in soils
- Desmedipham: Immobile in soil
- Ethofumesate: Moderately mobile in soils
- Metamitron: Moderately mobile in soils

12.5 Results of PBT and vPvB assessment

PBT and vPvB assessment
- Phenmedipham: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
- Desmedipham: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
- Ethofumesate: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
- Metamitron: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

12.6 Other adverse effects

Additional ecological information
No other effects to be mentioned.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product
Dispose of this product only by using according to the label, or at an approved landfill or other approved facility.

Contaminated packaging
Triple rinse containers. Recycle if possible. If allowed under local authority, burn if circumstances, especially wind direction permit, otherwise crush and bury in an approved local authority facility. Do not use container for any other purpose.

SECTION 14: TRANSPORT INFORMATION

This transportation information is not intended to convey all specific regulatory information relating to this product. It does not address regulatory variations due to package size or special transportation requirements.

ADR/RID/ADN
14.1 UN number 3082
14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE, METAMITRON SOLUTION)
14.3 Transport hazard class(es) 9
14.4 Packing group III
14.5 Environm. Hazardous Mark YES
Hazchem Code
IMDG
14.1 UN number  3082
14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE, METAMITRON SOLUTION)
14.3 Transport hazard class(es)  9
14.4 Packing group  III
14.5 Marine pollutant  YES

IATA
14.1 UN number  3082
14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE, METAMITRON SOLUTION)
14.3 Transport hazard class(es)  9
14.4 Packing group  III
14.5 Environm. Hazardous Mark  YES

14.6 Special precautions for user
See sections 6 to 8 of this Safety Data Sheet.

14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code
No transport in bulk according to the IBC Code.

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
Further information
HSNO approval-Nr.  HSR100882
HSNO Controls  See www.epa.govt.nz
ACVM Reg.  P8851
ACVM Condition  See www.foodsafety.govt.nz

SECTION 16: OTHER INFORMATION

Abbreviations and acronyms
ADN  European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways
ADR  European Agreement concerning the International Carriage of Dangerous Goods by Road
ATE  Acute toxicity estimate
CAS-Nr.  Chemical Abstracts Service number
Conc.  Concentration
ECx  Effective concentration to x %
The data given here is based on current knowledge and experience. The purpose of this Safety Data Sheet is to describe products in terms of their safety requirements. The above details do not imply any guarantee concerning composition, properties or performance of the product.

**Reason for Revision:**
Section 2: Hazards Identification. Section 3: Composition / Information on Ingredients. Section 8: Exposure Controls / Personal Protection. Section 11: Toxicological information on STOT (Specific Target Organ Toxicity) and CMR (Carcinogenic, Mutagenic and toxic to Reproduction).

Changes since the last version are highlighted in the margin. This version replaces all previous versions.